CN108663511B - Special diluent for alkaline phosphatase antigen antibody - Google Patents
Special diluent for alkaline phosphatase antigen antibody Download PDFInfo
- Publication number
- CN108663511B CN108663511B CN201810512182.9A CN201810512182A CN108663511B CN 108663511 B CN108663511 B CN 108663511B CN 201810512182 A CN201810512182 A CN 201810512182A CN 108663511 B CN108663511 B CN 108663511B
- Authority
- CN
- China
- Prior art keywords
- parts
- alkaline phosphatase
- antibody
- percent
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a special diluent for alkaline phosphatase antigen antibody. The special diluent comprises the following components in parts by mass: 92-95% of phosphate buffer solution, 1-3% of macromolecular hydrophilic compound, 0.2-0.5% of sodium ethylene diamine tetracetate, 0.01-0.02% of preservative, 1-3% of modified amino acid, 0.02-0.04% of anticoagulant, 0.05-0.12% of silk protein and 2.68-5.72% of nano silver powder. Compared with the prior art, the alkaline phosphatase antigen-antibody special diluent has simple components and good hydrophilicity, can stably mark the activity of the alkaline phosphatase antigen-antibody, has less required amount and reduces the production cost.
Description
Technical Field
The invention relates to the field of medicines, and particularly relates to a special diluent for an alkaline phosphatase antigen antibody.
Background
The quality of laboratory tests are related to the definite diagnosis and disease monitoring of patients, and in the field of blood infectious disease screening, the correctness of test results is also closely related to the safety of blood. The quality examination of the reagent, the indoor quality control of infectious disease detection and the participation in a proper indoor quality evaluation system are a series of methods for guaranteeing the detection quality. However, due to the deficiency of the preparation process of quality control products, the stability of quality control samples for reagent examination, indoor quality control and indoor quality evaluation in China is not high, and one important reason is that the result deviation of examination, quality control and quality evaluation is large due to the degradation of the quality control samples, so that on one hand, the correct judgment of the detection result of a laboratory is influenced, and even the accuracy of the test result is directly endangered, and on the other hand, each hospital clinical examination laboratory and blood station laboratory are in danger of management confusion and technical difficulty.
Alkaline phosphatase (ALP) is an enzyme widely present in animals, plants, and microorganisms. Alkaline phosphatase commonly used in clinical in vitro diagnosis is mainly obtained from calf intestinal mucosa and escherichia coli, and an antigen-antibody reagent marked with the alkaline phosphatase is an important component of a clinical immunological in vitro diagnosis kit. It is important how to ensure the activity of the stable alkaline phosphatase-labeled antigen-antibody.
Disclosure of Invention
In view of the disadvantages of the prior art, the present invention aims to provide a diluent for alkaline phosphatase antigen-antibody, which can stabilize the activity of alkaline phosphatase-labeled antigen-antibody and is easy to store.
A special diluent for alkaline phosphatase antigen antibodies comprises the following components in parts by mass: 92-95% of phosphate buffer solution, 1-3% of macromolecular hydrophilic compound, 0.2-0.5% of sodium ethylene diamine tetracetate, 0.01-0.02% of preservative, 1-3% of modified amino acid, 0.02-0.04% of anticoagulant, 0.05-0.12% of silk protein and 2.68-5.72% of nano silver powder.
The alkaline phosphatase antigen-antibody special diluent is characterized by comprising the following components in parts by mass: 93 percent of phosphate buffer solution, 1.5 percent of macromolecular hydrophilic compound, 0.3 percent of sodium ethylene diamine tetracetate, 0.015 percent of preservative, 2 percent of modified amino acid, 0.03 percent of anticoagulant, 0.1 percent of silk protein and 3.055 percent of nano silver powder.
As an improvement, the phosphate buffer comprises the following components by weight: 10-16 parts of sodium chloride, 2-5 parts of potassium chloride, 25-50 parts of potassium phosphate and 100 parts of deionized water.
In a further improvement, the phosphate buffer comprises the following components by weight: 12 parts of sodium chloride, 3 parts of potassium chloride, 45 parts of potassium phosphate and 180 parts of deionized water.
The improvement is that the macromolecular hydrophilic compound is formed by condensing cyclohexene oxide, chitosan and polyethylene glycol, wherein the molar ratio of the cyclohexene oxide to the chitosan to the polyethylene glycol is 2-4: 1-2: 3-5.
The improvement is that the preservative is one or a mixture of more of theophylline, sodium azide or lemongrass extract.
The modified amino acid is prepared by dissolving dopamine solution, adding amino acid, stirring uniformly, adding titanium dioxide powder, stirring continuously, and spray drying to obtain the modified amino acid.
Further improved, the temperature of spray drying is 50-65 ℃.
Has the advantages that:
compared with the prior art, the alkaline phosphatase antigen-antibody special diluent has simple components and good hydrophilicity, can stably mark the activity of the alkaline phosphatase antigen-antibody, has less required amount and reduces the production cost.
Detailed Description
The present invention will be described in further detail below with reference to specific examples.
Example 1
A special diluent for alkaline phosphatase antigen antibodies comprises the following components in parts by mass: 92% of phosphate buffer solution, 1% of macromolecular hydrophilic compound, 0.2% of sodium ethylene diamine tetracetate, 0.01% of theophylline, 1% of modified amino acid, 0.02% of anticoagulant, 0.05% of silk protein and 5.72% of nano silver powder.
The phosphate buffer solution comprises the following components in parts by weight: 10 parts of sodium chloride, 2 parts of potassium chloride, 25 parts of potassium phosphate and 100 parts of deionized water. The macromolecular hydrophilic compound is formed by condensing cyclohexene oxide, chitosan and polyethylene glycol, wherein the molar ratio of the cyclohexene oxide to the chitosan to the polyethylene glycol is 2: 1: 3.
the preparation method of the modified amino acid comprises the steps of dissolving a dopamine solution, adding the amino acid, uniformly stirring, adding titanium dioxide powder, continuously stirring, and carrying out spray drying at 50 ℃ to obtain the modified amino acid.
Diluting the hepatitis B core antibody concentrated solution marked with alkaline phosphatase with diluent according to the ratio of 1: 14000 to obtain the enzyme-labeled reagent. Placing the reagent in a 37 ℃ constant temperature box for accelerated test, culturing for 7 days and 14 days, taking out the enzyme-labeled reagent, adding the enzyme-labeled reagent into the hole of an ELISA plate coated with hepatitis B core antigen, adding hepatitis B core antibody for competition, reacting for 1h at 37 ℃ with the antigen antibody, washing the plate, developing with PNPP, and stopping reaction to measure absorbance. 99.45% of the activity remained after 7 days of acceleration at 37 ℃, 97.45% of the activity remained after 14 days, and 68.21% of the activity remained after 21 days.
Preparing a reagent by the same method, culturing at 5 ℃, adding into ELISA plate holes coated with hepatitis B core antigen, adding hepatitis B core antibody for competition, reacting for 1h, washing the plate, finally developing with PNPP, and stopping reaction to measure absorbance. After 7 days 92.12% of its activity remained, after 14 days 82.45% of its activity remained and after 21 days 52.48% of its activity remained.
Example 2
A special diluent for alkaline phosphatase antigen antibodies comprises the following components in parts by mass: 93 percent of phosphate buffer solution, 1.5 percent of macromolecular hydrophilic compound, 0.3 percent of sodium ethylene diamine tetracetate, 0.015 percent of sodium azide, 2 percent of modified amino acid, 0.03 percent of anticoagulant, 0.1 percent of silk protein and 3.055 percent of nano silver powder.
The phosphate buffer comprises the following components by weight: 12 parts of sodium chloride, 3 parts of potassium chloride, 45 parts of potassium phosphate and 180 parts of deionized water.
The macromolecular hydrophilic compound is formed by condensing cyclohexene oxide, chitosan and polyethylene glycol, wherein the molar ratio of the cyclohexene oxide to the chitosan to the polyethylene glycol is 3: 1: 4.
the preparation method of the modified amino acid comprises the steps of dissolving dopamine solution, adding the amino acid, uniformly stirring, adding titanium dioxide powder, continuously stirring, and carrying out spray drying at 60 ℃ to obtain the modified amino acid.
Diluting the hepatitis B core antibody concentrated solution marked with alkaline phosphatase with diluent according to the ratio of 1: 15000 to obtain the enzyme labeling reagent. Placing the reagent in a 37 ℃ constant temperature box for accelerated test, culturing for 7 days and 14 days, taking out the enzyme-labeled reagent, adding the enzyme-labeled reagent into the hole of an ELISA plate coated with hepatitis B core antigen, adding hepatitis B core antibody for competition, reacting for 1h at 37 ℃ with the antigen antibody, washing the plate, developing with PNPP, and stopping reaction to measure absorbance. 99.58% of the activity remained after 7 days of acceleration at 37 ℃, 97.87% of the activity remained after 14 days and 70.45% of the activity remained after 21 days.
Preparing a reagent by the same method, culturing at 5 ℃, adding into ELISA plate holes coated with hepatitis B core antigen, adding hepatitis B core antibody for competition, reacting for 1h, washing the plate, finally developing with PNPP, and stopping reaction to measure absorbance. After 7 days 93.45% of its activity remained, after 14 days 83.65% of its activity remained and after 21 days 65.48% of its activity remained.
Example 3
A special diluent for alkaline phosphatase antigen antibodies comprises the following components in parts by mass: 93 percent of phosphate buffer solution, 1.9 percent of hydrophilic polymer compound, 0.4 percent of sodium ethylene diamine tetracetate, 0.02 percent of lemongrass extract, 1.9 percent of modified amino acid, 0.03 percent of anticoagulant, 0.07 percent of silk protein and 2.68 percent of nano silver powder.
The phosphate buffer comprises the following components by weight: 16 parts of sodium chloride, 5 parts of potassium chloride, 50 parts of potassium phosphate and 200 parts of deionized water.
The macromolecular hydrophilic compound is formed by condensing cyclohexene oxide, chitosan and polyethylene glycol, wherein the molar ratio of the cyclohexene oxide to the chitosan to the polyethylene glycol is 4: 2: 5.
the preparation method of the modified amino acid comprises the steps of dissolving a dopamine solution, adding the amino acid, uniformly stirring, adding titanium dioxide powder, continuously stirring, and carrying out spray drying at 65 ℃ to obtain the modified amino acid.
Diluting the hepatitis B core antibody concentrated solution marked with alkaline phosphatase with diluent according to the ratio of 1: 14000 to obtain the enzyme-labeled reagent. Placing the reagent in a 37 ℃ constant temperature box for accelerated test, culturing for 7 days and 14 days, taking out the enzyme-labeled reagent, adding the enzyme-labeled reagent into the hole of an ELISA plate coated with hepatitis B core antigen, adding hepatitis B core antibody for competition, reacting for 1h at 37 ℃ with the antigen antibody, washing the plate, developing with PNPP, and stopping reaction to measure absorbance. 98.45% of its activity remained after 7 days of acceleration at 37 ℃, 93.89% of its activity remained after 14 days and 52.84% of its activity remained after 21 days.
Preparing a reagent by the same method, culturing at 5 ℃, adding into ELISA plate holes coated with hepatitis B core antigen, adding hepatitis B core antibody for competition, reacting for 1h, washing the plate, finally developing with PNPP, and stopping reaction to measure absorbance. 86.78% of its activity remained after 7 days, 72.58% of its activity remained after 14 days, and 50.85% of its activity remained after 21 days.
Example 4
A special diluent for alkaline phosphatase antigen antibodies comprises the following components in parts by mass: 92% of phosphate buffer solution, 1% of macromolecular hydrophilic compound, 0.2% of sodium ethylene diamine tetracetate, 0.01% of theophylline, 1% of modified amino acid, 0.02% of anticoagulant, 0.05% of silk protein and 5.72% of nano silver powder.
The phosphate buffer comprises the following components by weight: 16 parts of sodium chloride, 5 parts of potassium chloride, 50 parts of potassium phosphate and 200 parts of deionized water.
The macromolecular hydrophilic compound is formed by condensing cyclohexene oxide, chitosan and polyethylene glycol, wherein the molar ratio of the cyclohexene oxide to the chitosan to the polyethylene glycol is 4: 2: 5.
The preparation method of the modified amino acid comprises the steps of dissolving a dopamine solution, adding the amino acid, uniformly stirring, adding titanium dioxide powder, continuously stirring, and carrying out spray drying at 65 ℃ to obtain the modified amino acid.
Diluting the hepatitis B core antibody concentrated solution marked with alkaline phosphatase with diluent according to the ratio of 1: 14000 to obtain the enzyme-labeled reagent. Placing the reagent in a 37 ℃ constant temperature box for accelerated test, culturing for 7 days and 14 days, taking out the enzyme-labeled reagent, adding the enzyme-labeled reagent into the hole of an ELISA plate coated with hepatitis B core antigen, adding hepatitis B core antibody for competition, reacting for 1h at 37 ℃ with the antigen antibody, washing the plate, developing with PNPP, and stopping reaction to measure absorbance. 95.45% of its activity remained after 7 days of acceleration at 37 ℃, 87.45% of its activity remained after 14 days and 52.21% of its activity remained after 21 days.
Preparing a reagent by the same method, culturing at 5 ℃, adding into ELISA plate holes coated with hepatitis B core antigen, adding hepatitis B core antibody for competition, reacting for 1h, washing the plate, finally developing with PNPP, and stopping reaction to measure absorbance. After 7 days 86.54% of its activity remained, after 14 days 62.45% of its activity remained and after 21 days 50.65% of its activity remained.
Comparative example 1
The same procedure as in example 2 was repeated, except that the ordinary amino acid was replaced with the modified amino acid.
Diluting the hepatitis B core antibody concentrated solution marked with alkaline phosphatase with diluent according to the ratio of 1: 14000 to obtain the enzyme-labeled reagent. Placing the reagent in a 37 ℃ constant temperature box for accelerated test, culturing for 7 days and 14 days, taking out the enzyme-labeled reagent, adding the enzyme-labeled reagent into the hole of an ELISA plate coated with hepatitis B core antigen, adding hepatitis B core antibody for competition, reacting for 1h at 37 ℃ with the antigen antibody, washing the plate, developing with PNPP, and stopping reaction to measure absorbance. 85.62% of its activity remained after 7 days of acceleration at 37 ℃, 75.68% of its activity remained after 14 days and 45.58% of its activity remained after 21 days.
Preparing a reagent by the same method, culturing at 5 ℃, adding into ELISA plate holes coated with hepatitis B core antigen, adding hepatitis B core antibody for competition, reacting for 1h, washing the plate, finally developing with PNPP, and stopping reaction to measure absorbance. After 7 days, 58.46% of its activity remained, 45.57% of its activity remained after 14 days, and 32.82% of its activity remained after 21 days.
Research shows that the diluent can ensure the activity of the antigen and the antibody for stably marking the alkaline phosphatase at low temperature, and the used diluent has less volume when the same effect is ensured, so the cost of research and production is low, and the diluent is suitable for large-batch application.
The above description is only a preferred embodiment of the present invention, and the scope of the present invention is not limited thereto, and any simple modifications or equivalent substitutions of the technical solutions that can be obviously obtained by those skilled in the art within the technical scope of the present invention are within the scope of the present invention.
Claims (6)
1. The special alkaline phosphatase antigen-antibody diluent is characterized by comprising the following components in parts by mass: 92-95% of phosphate buffer solution, 1-3% of macromolecular hydrophilic compound, 0.2-0.5% of sodium ethylene diamine tetracetate, 0.01-0.02% of preservative, 1-3% of modified amino acid, 0.02-0.04% of anticoagulant, 0.05-0.12% of silk protein and 2.68-5.72% of nano silver powder, wherein the macromolecular hydrophilic compound is prepared by condensing cyclohexene oxide, chitosan and polyethylene glycol, and the molar ratio of the cyclohexene oxide to the chitosan to the polyethylene glycol is 2-4: 1-2: 3-5, the preparation method of the modified amino acid comprises the steps of dissolving dopamine solution, adding the amino acid, uniformly stirring, adding titanium dioxide powder, continuously stirring, and carrying out spray drying to obtain the modified amino acid.
2. The alkaline phosphatase antigen-antibody special diluent as claimed in claim 1, which comprises the following components in parts by mass: 93 percent of phosphate buffer solution, 1.5 percent of macromolecular hydrophilic compound, 0.3 percent of sodium ethylene diamine tetracetate, 0.015 percent of preservative, 2 percent of modified amino acid, 0.03 percent of anticoagulant, 0.1 percent of silk protein and 3.055 percent of nano silver powder.
3. The alkaline phosphatase antigen-antibody dedicated diluent according to claim 1, wherein the phosphate buffer comprises the following components by weight: 10-16 parts of sodium chloride, 2-5 parts of potassium chloride, 25-50 parts of potassium phosphate and 100 parts of deionized water.
4. The alkaline phosphatase antigen-antibody dedicated diluent according to claim 3, wherein the phosphate buffer comprises the following components by weight: 12 parts of sodium chloride, 3 parts of potassium chloride, 45 parts of potassium phosphate and 180 parts of deionized water.
5. The alkaline phosphatase antigen-antibody special diluent as claimed in claim 1, wherein the preservative is one or more of theophylline, sodium azide and lemongrass extract.
6. The alkaline phosphatase antigen-antibody dedicated diluent as claimed in claim 1, wherein the temperature of spray drying is 50-65 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810512182.9A CN108663511B (en) | 2018-05-25 | 2018-05-25 | Special diluent for alkaline phosphatase antigen antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810512182.9A CN108663511B (en) | 2018-05-25 | 2018-05-25 | Special diluent for alkaline phosphatase antigen antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108663511A CN108663511A (en) | 2018-10-16 |
| CN108663511B true CN108663511B (en) | 2021-01-29 |
Family
ID=63777672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810512182.9A Active CN108663511B (en) | 2018-05-25 | 2018-05-25 | Special diluent for alkaline phosphatase antigen antibody |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108663511B (en) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273908A (en) * | 1983-08-05 | 1993-12-28 | Wako Pure Chemical Industries, Ltd. | Stabilizing method for immuno active substances immobilized on insoluble carrier and its use in preparation of reagent for measuring physiologically active substances |
| US4931385A (en) * | 1985-06-24 | 1990-06-05 | Hygeia Sciences, Incorporated | Enzyme immunoassays and immunologic reagents |
| EP1816474B1 (en) * | 2004-11-25 | 2009-07-08 | DAINICHISEIKA COLOR & CHEMICALS MFG. CO. LTD. | Method of determining tropomyosin in chitosan |
| CN101561432B (en) * | 2009-05-27 | 2012-08-01 | 福建省洪诚生物药业有限公司 | Dilution being capable of maintaining high stability of enzyme marker solution |
| CN102628863B (en) * | 2012-04-19 | 2016-05-11 | 上海蓝怡科技有限公司 | Mark alkaline phosphatase antigen-antibody dilution |
| CN106771133A (en) * | 2016-11-30 | 2017-05-31 | 三诺生物传感股份有限公司 | A kind of composition and its application as enzyme mark compound preservation liquid |
| CN106501515A (en) * | 2016-12-07 | 2017-03-15 | 普菲特益斯生物科技（北京）有限公司 | CA215 detection kit and preparation method thereof and using method |
| CN107677809A (en) * | 2017-08-24 | 2018-02-09 | 菲鹏生物股份有限公司 | The detection kit of acute injury of kidney |
-
2018
- 2018-05-25 CN CN201810512182.9A patent/CN108663511B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108663511A (en) | 2018-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107118865B (en) | Cleaning solution | |
| CN102012433B (en) | Avian influenza virus H9 subtype positive blood serum and negative blood serum standard substances and preparation methods thereof | |
| CN107727869A (en) | Kit of antinuclear antibodies and preparation method thereof in a kind of measure serum | |
| CN102226808A (en) | Trypsinogen-2 chemiluminescent immunoassay kit and preparation method thereof | |
| CN104155449A (en) | Method and kit for detecting TORCH IgM antibodies and preparation method of kit | |
| CN114859031A (en) | Universal sample diluent for immunochromatography detection and preparation method thereof | |
| CN108663511B (en) | Special diluent for alkaline phosphatase antigen antibody | |
| CN1307422C (en) | An antigen-antibody dilution liquid and quality controlled produce formed thereby | |
| CN109443876A (en) | Hepatic fibrosis markers quality-control product and preparation method thereof | |
| CN106771218B (en) | It is a kind of detect HIV-1 p24 antigen kit and its application | |
| Medalia | “Color standards” for the colorimetric measurement of H-ion concentration pH 1.2 to pH 9.8 | |
| CN102004151A (en) | Avian influenza virus H9 subtype hemagglutination inhibition antigen standard substance and preparation method thereof | |
| CN105866427B (en) | A kind of composition and its application in infectious bronchitis of chicken antibody determination | |
| CN103288964B (en) | Albendazole-2-amino sulfone residue detection monoclonal antibody as well as preparation method and application thereof | |
| CN114414799A (en) | New coronavirus detection chromatography reagent strip, kit and preparation method thereof | |
| CN115389769A (en) | Test strip and kit for detecting cardiac troponin I and preparation method of test strip and kit | |
| CN110045123A (en) | A kind of carbohydrate antigen 242 magnetic microparticle chemiluminescence immune quantitative detection reagent box and preparation method thereof | |
| CN113740534A (en) | Novel coronavirus neutralizing antibody detection card and preparation method thereof | |
| CN113933522A (en) | Cat thyroid stimulating hormone fluorescent quantitative detection reagent and preparation method thereof | |
| CN107828855B (en) | Seminal plasma neutral alpha-glucosidase detection kit and application thereof | |
| CN110441536A (en) | Detect the chemical luminescence reagent kit of vitamin B12 | |
| WO2012128658A1 (en) | Method for producing a panel of sera with hbsag subtypes ad and ay for quality control in hepatitis в diagnostics | |
| CN111175515A (en) | Two-in-one quality control substance of serum amyloid A and C reactive protein and preparation method thereof | |
| CN110579604B (en) | Chimeric ELISA kit for quantitatively detecting florfenicol in eggs and preparation method thereof | |
| CN109870578A (en) | A kind of cystatin C detection kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210115 Address after: 210046 room 602, building 1, phase I, Jingang Kechuang Park, No.1 Kechuang Road, Yaohua street, Qixia District, Nanjing City, Jiangsu Province Applicant after: Nanjing sko volt new materials Co.,Ltd. Address before: 5 / F, 101 Jialingjiang Road, high tech Zone, Suzhou City, Jiangsu Province Applicant before: SUZHOU YOUJUN ENVIRONMENT SCIENCE & TECHNOLOGY Co.,Ltd. |